Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly targeted therapies in some cases, KRAS has rem...
Main Authors: | Sandy, Peter, Meylan, Etienne, Reiling, Jan H., Hoersch, Sebastian, Barbie, David A., Tamayo, Pablo, Boehm, Jesse S., Kim, So Young, Moody, Susan E., Dunn, Ian F., Schinzel, Anna C., Scholl, Claudia, Frohling, Stefan, Chan, Edmond M., Sos, Martin L., Michel, Kathrin, Mermel, Craig H., Sabatini, David, Lander, Eric Steven, Jacks, Tyler E |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | en_US |
Published: |
Nature Publishing Group
2014
|
Online Access: | http://hdl.handle.net/1721.1/84607 https://orcid.org/0000-0001-5785-8911 https://orcid.org/0000-0002-1446-7256 |
Similar Items
-
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
by: Scholl, Claudia, et al.
Published: (2015) -
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
by: Sandy, Peter, et al.
Published: (2015) -
Differential Effector Engagement by Oncogenic KRAS
by: Tina L. Yuan, et al.
Published: (2018-02-01) -
Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.
by: Reina E Ito, et al.
Published: (2021-01-01) -
Oncogenic KRAS: Signaling and Drug Resistance
by: Hyeon Jin Kim, et al.
Published: (2021-11-01)